Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey

Abstract

The short- and long-term prognoses of HIV-negative patients with anal squamous cell carcinoma were good, and low-grade toxicity was rare, thereby demonstrating that these patients can be successfully treated in a real-life setting with favorable outcomes.

Outcomes of patients with anal cancer treated with definitive chemoradiation: A single centre experience

“…Yuan et al [ 13 ] reported the differences in 5-year survival rates between node-negative and node-positive disease (76.7% versus 70.3%), and between stages I–II and stages III–IV (83.6% versus 71.2%), respectively. Esin et al [ 14 ] also reported an improvement in progression-free survival (PFS) with a lower T stage [ 14 ]. In addition, immunochemical staining of p16 also has prognostic value, with p16-positive tumours having a 2-year relapse-free rate of 78.2%, compared to 49.0% in p16-negative tumours, as reported by Wakeham et al [ 15 ].…”

“…In our study, more than two-thirds of the participants had complete radiological response following CRT, which is consistent with the responses seen in previous studies [ 16 – 20 ]. In a Turkish study evaluating HIV-negative patients, 100% response rate was demonstrated with the CRT approach in patients with ASCC, all of whom were CRs [ 14 ]. A similar study of 48 patients with ASCC was conducted by Day et al [ 21 ] in which CRs were documented in 79% of the patients via F-fluorodeoxyglucose positron emission tomography [ 21 ].…”